Clinical Trial Update: Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating disitamab vedotin in combination with trastuzumab in patients with HER2-positive gastric cancer or HER2-positive gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING